AGM
CYTK icon

Alpine Global Management’s Cytokinetics CYTK Stock Holding History

Alpine Global Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,000
Closed -$381K – 279
2025
Q4 		$381K Buy
+6,000
New +$373K 0.08% 114
2024
Q3 		– Sell
-12,468
Closed -$676K – 232
2024
Q2 		$676K Buy
+12,468
New +$753K 0.12% 144

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Alpine Global Management's CYTK Position: Q1 2026 in Review

Alpine Global Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 6,000 shares — an estimated $381K sold.

Alpine Global Management first reported a position in CYTK in Q2 2024 and held it in 2 quarters. The position peaked at $676K in Q2 2024. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Alpine Global Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Alpine Global Management sold 6,000 Cytokinetics shares in Q1 2026, an estimated $381K.
  • Alpine Global Management first reported a position in Cytokinetics in Q2 2024 and held it in 2 quarters.
  • Alpine Global Management's Cytokinetics position peaked at $676K in Q2 2024.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Alpine Global Management's 13F filing for Q1 2026, filed 15 May 2026.